Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

NCT06491563 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

For Treatment of Chronic Hepatitis B Virus Infection

Interventions

BIOLOGICAL: BRII-179
DRUG: BRII-835 (VIR-2218)
BIOLOGICAL: PEG-IFNα

Sponsor

Brii Biosciences Limited

Collaborators

[object Object]